Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration.
Mult Scler Relat Disord
; 27: 131-132, 2019 Jan.
Article
em En
| MEDLINE
| ID: mdl-30384197
ABSTRACT
BACKGROUND:
Alemtuzumab administration is known to cause secondary autoimmune disease but has not been associated with the development of neurologic autoimmune conditions. Lambert-Eaton myasthenic syndrome (LEMS) is caused by autoantibodies directed against calcium channels on the neuromuscular junction. CASE REPORT We report a case of a patient with relapsing-remitting multiple sclerosis (RRMS) treated with alemtuzumab who develop generalized weakness initially attributed to progression of MS but eventually determined to be due to LEMS.CONCLUSION:
Alemtuzumab treatment can result in the development of neurologic autoimmune conditions that could mimic MS progression.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Síndrome Miastênica de Lambert-Eaton
/
Esclerose Múltipla Recidivante-Remitente
/
Alemtuzumab
/
Fatores Imunológicos
Tipo de estudo:
Risk_factors_studies
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Mult Scler Relat Disord
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Estados Unidos